These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48 related articles for article (PubMed ID: 2236460)
1. Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia. Jody D; Lieberman JA; Geisler S; Szymanski S; Alvir JM Psychopharmacol Bull; 1990; 26(2):224-30. PubMed ID: 2236460 [TBL] [Abstract][Full Text] [Related]
2. The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls. Koreen AR; Lieberman JA; Alvir J; Chakos M Neuropsychopharmacology; 1997 Jan; 16(1):61-8. PubMed ID: 8981389 [TBL] [Abstract][Full Text] [Related]
3. Prediction of outcome in first-episode schizophrenia. Lieberman JA J Clin Psychiatry; 1993 Mar; 54 Suppl():13-7. PubMed ID: 8097192 [TBL] [Abstract][Full Text] [Related]
4. [Maintenance electroconvulsive therapy and treatment of refractory schizophrenia]. Lévy-Rueff M; Jurgens A; Lôo H; Olié JP; Amado I Encephale; 2008 Oct; 34(5):526-33. PubMed ID: 19068343 [TBL] [Abstract][Full Text] [Related]
5. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)]. Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451 [TBL] [Abstract][Full Text] [Related]
6. Neurocognitive correlates of response to treatment in formal thought disorder in patients with first-episode schizophrenia. Goldstein RZ; Giovannetti T; Schullery M; Zuffante PA; Lieberman JA; Robinson DG; Barr WB; Bilder RM Neuropsychiatry Neuropsychol Behav Neurol; 2002 Jun; 15(2):88-98. PubMed ID: 12050471 [TBL] [Abstract][Full Text] [Related]
7. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Chakos MH; Mayerhoff DI; Loebel AD; Alvir JM; Lieberman JA Psychopharmacol Bull; 1992; 28(1):81-6. PubMed ID: 1609046 [TBL] [Abstract][Full Text] [Related]
8. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses]. Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M Encephale; 1995; 21(6):417-24. PubMed ID: 8674466 [TBL] [Abstract][Full Text] [Related]
9. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428 [TBL] [Abstract][Full Text] [Related]
10. Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response. Jäger M; Riedel M; Schmauss M; Pfeiffer H; Laux G; Naber D; Gaebel W; Huff W; Schmidt LG; Heuser I; Buchkremer G; Kühn KU; Rüther E; Hoff P; Gastpar M; Bottlender R; Strauss A; Möller HJ Psychiatry Res; 2008 Apr; 158(3):297-305. PubMed ID: 18280582 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Reynolds GP; Yao Z; Zhang X; Sun J; Zhang Z Eur Neuropsychopharmacol; 2005 Mar; 15(2):143-51. PubMed ID: 15695058 [TBL] [Abstract][Full Text] [Related]
12. [Generic quetiapine in the treatment of acute schizophrenia and schizoaffective disorder]. György B; Robert K; László C; Andrea J; Neuropsychopharmacol Hung; 2008 Dec; 10(5):293-303. PubMed ID: 19419015 [TBL] [Abstract][Full Text] [Related]
13. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373 [TBL] [Abstract][Full Text] [Related]
14. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients. Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918 [TBL] [Abstract][Full Text] [Related]
15. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Kinon BJ; Kane JM; Chakos M; Munne R Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184 [TBL] [Abstract][Full Text] [Related]
16. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Lieberman JA; Alvir J; Geisler S; Ramos-Lorenzi J; Woerner M; Novacenko H; Cooper T; Kane JM Neuropsychopharmacology; 1994 Oct; 11(2):107-18. PubMed ID: 7840862 [TBL] [Abstract][Full Text] [Related]
17. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG; Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173 [TBL] [Abstract][Full Text] [Related]
18. Treatment of neuroleptic-resistant schizophrenic relapse. Kinon BJ; Kane JM; Johns C; Perovich R; Ismi M; Koreen A; Weiden P Psychopharmacol Bull; 1993; 29(2):309-14. PubMed ID: 7904762 [TBL] [Abstract][Full Text] [Related]
19. [Psychopathology of schizophrenia and brain imaging]. Gross G; Huber G Fortschr Neurol Psychiatr; 2008 May; 76 Suppl 1():S49-56. PubMed ID: 18461545 [TBL] [Abstract][Full Text] [Related]